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A.M. Fink,* N. Herzog, B. Borst-Krafek, W. Jurecka and A. SteinerDepartment of Dermatology, Wilhelminenspital, Montleartstr. 37, 1160 Vienna, AustriaObjectives. To assess the long-term mortality in patients with thrombosis of the vena cava, iliac and femoral veins.
Design. Registry study.
Materials. Between 1992 and 2000, 212 consecutive patients with acute pelvic vein thrombosis diagnosed by duplex
sonography were examined by magnetic resonance imaging (MRI) to determine the most proximal extent of the thrombus.
MRI revealed a thrombosis in the inferior vena cava in 46 patients (22%), in the iliac vein in 142 patients (67%), and in the
femoral vein in 24 patients (11%).
Methods. The vital status of the patients was investigated in April 2004 using the Austrian National Registry and the
Cause of Death Register.
Results. A total of 211 patients of the original 212 patients were monitored over a mean follow-up period of 91 months.
Seventy-two of 211 patients (34%) had died. There was no significant difference in the long-term mortality, the survival
period or the occurrence of fatal pulmonary embolism (PE) between previously diagnosed vena cava, iliac vein, or femoral
vein thrombosis.
Conclusions. Extension of a thrombus into the inferior caval vein in patients considered to have a pelvic vein thrombosis has
no impact on long-term mortality or the development of fatal PE compared to those patients with thrombus limited to more
distal veins.Keywords: Long-term mortality; Fatal pulmonary embolism; Survival; Inferior vena cava thrombosis; Follow-up.Introduction
Thrombotic involvement of the inferior vena cava is a
common occurrence in patients with proximal deep
vein thrombosis of the lower limb.1–4
In a previous study,4 we showed by magnetic
resonance imaging (MRI) that thrombus extends into
the inferior vena cava in 22% of patients with a pelvic
deep vein thrombosis diagnosed by duplex sono-
graphy. In our patients extension of thrombus into the
inferior vena cava was not associated with a greater
frequency of pulmonary embolism or higher mortality
during hospitalisation or during an initial follow-up
period of 4 weeks.
There was no difference in short-term mortality in
our patients. However, long-term mortality in patients
with inferior vena cava thrombosis is largely
unknown.5,6 The aim of the present follow-up study
was to investigate the long-term mortality of thising author. Astrid M. Fink, MD, Department of
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been enrolled in our previous study.Material and MethodsStudy background
Between 1992 and 2000, a consecutive series of 212
patients considered to have a deep vein thrombosis
proximal to the inguinal ligament, diagnosed by
duplex ultrasound, were investigated by magnetic
resonance imaging (MRI) to assess the most proximal
extent of the thrombus in the pelvic veins. The design,
methods and results of this investigation were
reported in a previous publication.4 Using MRI to
assess the most proximal extent of the thrombus in 212
patients, it was found that the deep vein thrombosis
(DVT) extended into the inferior vena cava in 46
patients (22%), into iliac veins in 142 patients (67%),
and was confined to the femoral veins in 24 patients
(11%). The frequency of pulmonary embolism wasEur J Vasc Endovasc Surg 31, 200–203 (2006)
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Long-term Mortality and Caval Vein Thrombosis 201unrelated to the proximal extent of the thrombus. All
patients received subcutaneous low molecular weight
heparin (Fragmin, Pharmacia, Stockholm, Sweden) at
a dose of 100 IU/kg body weight twice daily followed
by oral anticoagulation with coumarin (Marcoumarw
from Roche, Basle, Switzerland). The treatment regime
of oral anticoagulation was independent of the extent
of the thrombus. Oral anticoagulation was continued
for 6 months in patients with the first thrombotic event
and without any risk factors such as a thrombophilia.
Patients with recurrent thrombosis received oral
anticoagulation for at least 1 year.
All patients were followed up for at least 4 weeks.
During this period no patient died due to fatal
pulmonary embolism.Follow-up investigation
Follow-up studies were performed in April 2004 to
investigate the vital status of all patients. For this
purpose we used the personal identification number of
every patient, which in Austria is a 10-digit code. We
linked the patient’s identification number with the
nationwide Austrian Health Care Register and the
Cause of Death Register to assess the vital status of
the patients as well as the causes of death. The
Austrian Cause of Death Register documents the
dates and causes of all deaths in Austria. The causes
of death until April 2004 were encoded according to
the International Classification of Diseases (ICD-9
until the end of 2000, thereafter ICD-10), based on
the data noted in the death certificates, which had been
filled out by physicians, in hospitals, by general
practitioners, or in forensic medicine. The follow-up
period ended on April 1, 2004.Study population
Of 212 patients included in the previous study, one
was lost to follow-up because of emigration. The
remaining 211 patients (100 men and 111 women) were
followed up and included in the present study.Statistics
All variables were summarised using frequency distri-
butions for categorical variables and mean and standard
deviation for continuous variables. Comparisons
between groups were performed using Kruskall–Wallis-
test or Mann–Whitney U-test for continuous variables
and Chi-square-test for categorical variables. p values of
%0.05 were considered statistically significant.ResultsPatient characteristics
In all, 211 of 212 patients (99.5%) (100 men and 111
women) were followed up. One patient with iliac
vein thrombosis was lost to follow-up. The mean
duration of follow-up was 91 months (range, 41–
141 months). Patient characteristics are summarised
in Table 1.Long-term mortality
Seventy-two (34%; 34 men, 38 women) of 211 patients
died during the follow-up period. Fifteen of 46
patients (33%) with previously diagnosed inferior
vena cava thrombosis died. Among 141 patients in
whom iliac vein thrombosis was established by MRI,
48 (34%) died. Of 24 patients in whom the thrombus
was confined to the femoral veins, nine (38%) died.
There was no significant difference in long-term
mortality between patients with previously diagnosed
inferior vena cava thrombosis, iliac vein thrombosis or
femoral vein thrombosis (pZ0.88).
The deaths occurred within 38 months of the
previously diagnosed thrombo-embolic event; there
was no significant difference between patients with
previously diagnosed inferior vena cava, iliac vein, or
femoral vein thrombosis (pZ0.36) (Table 1). The mean
age of the deceased patients was 76 years (range, 30–96
years).
The causes of death were known in all cases. These
included cardiac disease (nZ19), malignant disease
(nZ20), myocardial infarction (nZ10), pneumonia
(nZ6), ischaemic stroke (nZ4), multiple trauma
(nZ2), fatal pulmonary embolism (nZ9) and fatal
major bleeding (nZ2).Fatal bleeding
Fatal major bleeding occurred in two patients. One
patient died because of rupture of an abdominal
aneurysm 104 months following a femoral vein
thrombosis. The other had fatal cerebral bleeding 9
months following iliac vein thrombosis. The latter
patient was still receiving oral anticoagulant therapy
at the time of death.Fatal pulmonary embolism
Only nine of 211 patients (4.3%) died because of fatal
pulmonary embolism during the follow-up period. InEur J Vasc Endovasc Surg Vol 31, 2 2006
Table 1. Patient characteristics and long-term mortality
Caval vein thrombosis Iliac vein thrombosis Femoral vein thrombosis
Number of patients nZ212 46 (22%) 142* (67%) 24 (11%)
Deceased patients 15/46 (33%) 48/142 (34%) 9/24 (38%) pZ0.88
Survival period of deceased patients
[months]
29 42 33 pZ0.36
Follow-up period for survivors [months] 86 87 100 pZ0.17
Fatal pulmonary embolism 2/46 (4.3%) 6/142 (4.2%) 1/24 (4.2%) pZ0.99
Major bleeding 0/46 1/142 (0.7%) 1/24 (4.2%)
* One patient was lost to follow-up.
A. M. Fink et al.202six of these patients the diagnosis was verified by
autopsy. In one patient fatal pulmonary embolism was
accompanied by malignant disease at the time of
death. In terms of medical history the fatal pulmonary
embolism was the second thrombo-embolic event in
the lives of three patients, the third event in the lives of
another three patients, and the fourth event in the life
of one patient. At the time of death three patients with
fatal pulmonary embolism were still receiving antic-
oagulant therapy.
There was no significant difference in fatal pulmon-
ary embolism between patients with previously
diagnosed inferior vena cava, iliac vein, or femoral
vein thrombosis (pZ0.99). With regard to mean
survival, fatal pulmonary embolism occurred within
an average of 18 months after previous DVT. This was
significantly shorter than the mean survival of the
remaining deceased patients (pZ0.01). The ages of
those patients who died due to fatal pulmonary
embolism were comparable with those of the other
deceased patients (pZ0.59).Discussion
Since, thrombotic involvement of the inferior vena
cava is a common occurrence in patients with
proximal deep vein thrombosis of the lower extre-
mity,1–4,7 the aim of the present study was to
investigate long-term mortality in patients with
inferior caval vein thrombosis. The three principal
findings of the present study are detailed in the
following.
Firstly, there was no significant difference in long-
term mortality between the patients with a previous
inferior vena cava, iliac, or femoral deep vein
thrombosis. In concurrence with the published litera-
ture, death was most commonly due to cancer,
cardiovascular disease or myocardial infarction.8,9
The overall long-term mortality rate of 34% within a
mean follow-up period of 91 months is comparable
with the rates reported in previous studies.8,10,11Eur J Vasc Endovasc Surg Vol 31, 2 2006Secondly, fatal pulmonary embolism occurred in
nine of 211 patients (4.3%). This was comparable with
previously published data.8–10,12–14 The lowest rate of
fatal PE was 1.5% observed by Douketis et al.12 The
highest rate of fatal PE was 4.5% observed by
Decousus et al.9 The relatively high rate of fatal PE in
the present study is probably due to the higher
autopsy rate compared to other studies.10,15
The mean survival of patients with fatal pulmonary
embolism was significantly shorter than the mean
survival of the other deceased patients. It should be
noted that in the present study the frequency of
pulmonary embolism was not increased among
patients with previously diagnosed inferior vena
cava thrombosis, although none of the previously
enrolled patients received an inferior vena cava filter
(IVF).
Third, major bleeding was a rare event in our study.
Only two of 211 patients (0.95%) died because of fatal
major bleeding; this finding concurs with previously
published data.8,10,16 In no case was major bleeding
associated with the extent of the previously diagnosed
DVT.
The present study has a number of limitations.
Firstly, since patients with clinically massive pulmon-
ary embolism who need intensive care were not
included, the present findings may not apply to
these patients. Secondly, the study is based on data
from a registry. Detailed patient data concerning the
development of recurrent DVT or the occurrence of
post-thrombotic syndrome were not available. Fur-
thermore, since the patients were studied at a single
centre, a hospital-specific selection bias cannot be
excluded.
The strengths of the study are its long follow-up
period and the large patient sample. Studies investi-
gating long-term survival in patients with inferior
vena cava thrombosis are scarce.17 The follow-up
period is usually limited to 1–3 years;15,18 a few studies
extend to 8 years.8,11,19 A further strength of the
present study is that the general autopsy rate (34.7%)
was higher than the rates reported in previous
studies.15
Long-term Mortality and Caval Vein Thrombosis 203In conclusion, the present investigation showed that
the extension of thrombi into the inferior vena cava in
patients considered to have a pelvic vein thrombosis
has no impact on long-term mortality or the develop-
ment of fatal pulmonary embolism within a mean
follow-up period of 91 months.References
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